Treatment of granuloma annulare and related granulomatous diseases with sulphasalazine: a series of 16 cases.

Szczegóły
Abstrakt

Tytuł:: Treatment of granuloma annulare and related granulomatous diseases with sulphasalazine: a series of 16 cases.
Autorzy:: Yang YW; Mayo Clinic, Scottsdale, AZ, USA.
Lehrer MD; Mayo Clinic, Scottsdale, AZ, USA.
Mangold AR; Mayo Clinic, Scottsdale, AZ, USA.
Yiannias JA; Mayo Clinic, Scottsdale, AZ, USA.
Nelson SA; Mayo Clinic, Scottsdale, AZ, USA.
Pittelkow MR; Mayo Clinic, Scottsdale, AZ, USA.
Źródło:: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Jan; Vol. 35 (1), pp. 211-215. Date of Electronic Publication: 2020 Jul 21.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992-
MeSH Terms:: Dermatitis*/drug therapy
Granuloma Annulare*/drug therapy
Granuloma, Giant Cell*
Aged ; Aged, 80 and over ; Female ; Granuloma ; Humans ; Male ; Middle Aged ; Sulfasalazine/therapeutic use
References:: Piette EW, Rosenbach M. Granuloma annulare: pathogenesis, disease associations and triggers, and therapeutic options. J Am Acad Dermatol 2016; 75: 467-479.
Limas C. The spectrum of primary cutaneous elastolytic granulomas and their distinction from granuloma annulare: a clinicopathological analysis. Histopathology 2004; 44: 277-282.
Peroni A, Colato C, Schena D, Gisondi P, Girolomoni G. Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern. Br J Dermatol. 2012; 166:775-783.
Chen WT, Hsiao PF, Wu YH. Spectrum and clinical variants of giant cell elastolytic granuloma. Int J Dermatol. 2017; 56: 738-745.
Wolf R, Matz H, Orion E, Tuzun B Tuzun Y. Miscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indications. Clin Dermatol 2002; 20: 531-546.
Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. Ann Allergy Asthma Immunol 2008; 100: 403-411; quiz 12-4, 68.
Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010; 62: 191-202, quiz 3-4.
Dabski K Winkelmann RK. Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J Am Acad Dermatol 1989; 20: 39-47.
Min MS, Lebwohl M. Treatment of recalcitrant granuloma annulare (GA) with adalimumab: a single-center, observational study. J Am Acad Dermatol 2016; 74: 127-133.
Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am J Ther 2001; 8: 123-143.
Dixon SJ, Lemberg KM, Lamprecht MR et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-1072.
Barrera P, Boerbooms AM, van de Putte LB, van der Meer JW. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996; 25: 234-253.
Rodenburg RJ, Ganga A, van Lent PL, van de Putte LB, van Venrooij WJ. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 2000; 43: 1941-1950.
Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990; 20: 217-224.
Bissonnette EY, Enciso JA, Befus AD. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. J Immunol 1996; 156: 218-223.
Paniker U Levine N. Dapsone and sulfapyridine. Dermatol Clin 2001; 19: 79-86, viii.
Kettle AJ Winterbourn CC. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 1991; 41: 1485-1492.
Nurmohamed MT Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005; 65: 661-694.
Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed) 1986; 293: 420-423.
Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-539.
Substance Nomenclature:: 3XC8GUZ6CB (Sulfasalazine)
Entry Date(s):: Date Created: 20200328 Date Completed: 20210514 Latest Revision: 20210514
Update Code:: 20240105
DOI:: 10.1111/jdv.16356
PMID:: 32216136
: Czasopismo naukowe

Full Text Finder

Background: Granuloma annulare (GA) and the related annular elastolytic giant cell granuloma (AEGCG) and interstitial granulomatous dermatitis (IGD) are idiopathic histiocytic inflammatory disorders, which are frequently recalcitrant to treatment.
Objectives: Evaluate the efficacy of sulphasalazine in treating GA, AEGCG and IGD.
Methods: Sixteen patients were identified with granulomatous disease who were treated with sulphasalazine between September 2015 and September 2019. Outcomes were based on patients' and providers' subjective evaluations.
Results: Sixteen patients were included in the study (ages 56-89, four male and twelve female). Previous treatments were attempted in fifteen patients. Clinical improvement was seen in fourteen patients (87.5%). Initial improvement was noted within a mean (SD) of 66.4 (35.1) days after starting therapy, with increasing benefits over time. Ten patients (62.5%) reported complete or near-complete clearance, three patients (18.8%) reported significant improvement, and one (6.3%) reported partial improvement. Twelve patients elected to stop or reduce therapy, resulting in relapse or worsening in five patients.
Conclusions: Sulphasalazine may be considered as treatment for GA and GA-related conditions.
(© 2020 European Academy of Dermatology and Venereology.)

Informacja